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Antimicrobial susceptibilityAbstract Nosocomial spread of B. cepacia complex (Bcc) isolates amongst non-CF patients has
been documented, where inadequate laboratory identiﬁcation and limited treatment options are
considered the main obstacles hindering accurate diagnosis and thus proper therapeutic outcome.
The present study aimed to detect the isolation percentage of Bcc from patients in Alexandria
Medical University Hospital (AMUH) according to site of infection (specimen), throughout a
6 month period. Out of 2079 specimens submitted to the microbiology laboratory, 35 strains were
isolated on BCSA and biochemically identiﬁed as Bcc for the ﬁrst time in this laboratory.
The highest rate of isolation of Bcc isolates was from pus (85.7%) isolated from patients in the burn
unit. Antibiotic susceptibility tests revealed that all Bcc isolated were Multi Drug Resistant (MDR),
the highest susceptibility was to meropenem (88.5%) followed by ceftazidime (60%), tobramycin,
chloramphenicol, piperacillin–tazobactam and tetracycline, while all strains were resistant to co-
trimoxazole and ciproﬂoxacin.
Minimal Inhibitory Concentration (MIC) determining tests showed that only 11.5% were resis-
tant to meropenem at MIC > 16 lg/ml, while 40% of the strains were resistant to ceftazidime at
MIC > 32 lg/ml. Those results for the time being indicate that meropenem is the best therapeutic
option for Bcc infections in AMUH.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
B. cepacia complex is well recognized as a signiﬁcant pathogen
associated with colonization and pulmonary infection in cystic
ﬁbrosis (CF) patients. However, the pathogenicity of Bcc is not
always limited to CF or immunocompromised patients. Sev-
eral surveys now report the increasing or simultaneous persis-
tence of Pseudomonas aeruginosa, Acinetobacter spp. and
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as the emergence of newer nosocomial non-fermentative gram
negative bacilli (NFGNB) such as Bcc that causes serious
problems in clinical settings because of its high transmissibility
between hospitalized patients and its multiple drug resis-
tance.1–3 It is associated with a wide variety of infections
among hospitalized patients who are usually infected via
contaminated equipment or exposure to contaminated
solutions. The infections usually include pneumonia, bactere-
mia, skin and soft tissue infection and genitourinary tract
infection.4–6
Generally, in the literature reports of nosocomial B. cepacia
infections are usually restricted to nosocomial epidemics or
outbreaks. Reports of sporadic cases of B. cepacia nosocomial
infections are rare, probably due to the lack of speciﬁc labora-
tory tests in routine testing in most hospitals, so B. cepacia has
been ambiguously reported as NFGNB or simply Pseudomo-
nas spp. This was the case in the routine microbiology labora-
tory in our department before this study. This also explains the
lack of reports about the prevalence of B. cepacia infections in
Egypt and many countries.7–9
In routine clinical laboratories, the identiﬁcation of puta-
tive Bcc isolates is generally performed using a combination
of selective media, conventional biochemical analysis and/or
commercial systems. Several different media have been devel-
oped for the selective isolation of Bcc isolates from different
specimens10–12 such as B. cepacia selective agar (BCSA), Pseu-
domonas cepacia (PC) agar, or oxidation-fermentation poly-
myxin-bacitracin-lactose (OFPBL) agar.13
BCSA is more enriched than OFPBL or PCA, where yeast
extract and casein provide a rich variety of ingredients that
overcome the nutritional deﬁciencies which may prevent some
strains of B. cepacia from growth on other selective media.
Organisms not belonging to the Bcc that are capable of growth
on BCSA include B. gladioli, Ralstonia spp. and Pandoraea
spp.14,15
Bcc has intrinsic resistance and is one of the most antimi-
crobial-resistant organisms encountered. Therefore, it needs
to be correctly identiﬁed and differentiated from P. aeruginosa
as Bcc has inherently contrasting susceptibility pattern to that
of P. aeruginosa. Bcc is intrinsically resistant to antimicrobial
agents such as aminoglycosides, ﬁrst-and second-generation
cephalosporins, antipseudomonal penicillins and polymyxins.
Thus giving extreme value to the proper identiﬁcation of B.
cepacia.9,16
The present study aimed to detect the isolation percentage
of Bcc from patients in the different wards of the Alexandria
Main University Hospital (AMUH) according to the site of
infection (specimen) throughout a period of 6 months (June
to December 2011) and to determine their antibiotic suscepti-
bility pattern.2. Methods
The present study was conducted on 2079 specimens submitted
to the routine microbiology lab as a part of routine diagnostic
services to the patients admitted in AMUH, which is a 1000
bed tertiary teaching hospital in Alexandria, Egypt, through-
out a period of 6 months.
All Gram negative bacilli isolates that grew as non lactose
fermenting colonies on MacConkey’s agar and were oxidasepositive, were maintained as stock culture in glycerol broth
and stored at 20 C to be further tested.
The stored isolates were ﬁrst subcultured on MacConkey’s
agar, then picked and inoculated on BCSA (Oxoid, United
Kingdom) and incubated at 37 C for 48 to 72 h.17 Reference
strain of Pseudomonas aeruginosa ATCC 27853 was also cul-
tured on BCSA as negative control strain.
All strains that grew on BCSA were further subjected to
presumptive identiﬁcation by the following biochemical tests:18
- Motility (Oxoid, United Kingdom).
- lysine decarboxylation (Oxoid, United Kingdom).
- Ornithine decarboxylation (Oxoid, United Kingdom).
All isolates that were found to be ornithine decarboxylase
positive, lysine decarboxylase positive and motile were selected
for conﬁrmation of their identiﬁcation by RapID NF Plus
system.
2.1. RapID NF plus (Remel, Lexena, Kans.)
Suspension of sufﬁcient growth from MacConkey’s agar plate
in RapID inoculation ﬂuid (1 ml) was prepared to achieve a
visual turbidity equal to #1 to #3 McFarland turbidity stan-
dard, then used to inoculate the RapID NF plus panel fol-
lowed by incubation at 37 C in the incubator for 4 h. All 10
tests were ﬁrst scored before the addition of reagent providing
the ﬁrst test result. Then the bifunctional cavities were scored
again after the addition of reagent to provide the second test
result, using RapID NF Plus color guide provided by manu-
facturer. The results were then scored to provide a microcode,
then the web based program ERIC (Electronic RapID com-
pendium) was used for identiﬁcation, based on the derived
microcodes obtained from panels.
2.2. Antibiotic susceptibility testing
2.2.1. Modiﬁed Bauer Kirby disk diffusion susceptibility test
Bcc isolates were tested for their susceptibility to different anti-
microbial agents and interpreted according to CLSI (2010).19
Mueller–Hinton agar (Oxoid, United Kingdom) plates were
inoculated with a bacterial suspension equivalent to a 0.5
McFarland Standard, then the following antibiotic susceptibil-
ity disks (Oxoid) were applied:
Ceftazidime (CAZ) 30 lg, Meropenem (MEM) 10 lg, Tet-
racycline (TE) 30 lg, Trimethoprim-Sulphamethoxazole
(SXT) 1.25/23.75 lg, Tobramycin (TOB) 10 lg, Chloramphen-
icol (C) 30 lg, Piperacillin–Tazobactam (TZP) 100/10 lg, Cip-
roﬂoxacin (CIP) 30 lg. Zones of growth inhibition were
measured after overnight incubation at 37oC.
2.2.2. Microbroth dilution method was used to determine the
MIC for MEM and CAZ
All Bcc strains were tested for their susceptibility to Ceftazi-
dime and Meropenem by microbroth dilution technique and
using Pseudomonas aeruginosa ATCC 27853 as a control.20
For each antibiotic, a stock solution was prepared at a con-
centration of 1000 lg/ml, then two fold serial dilution of the
antibiotic was done in cation adjusted Mueller Hinton broth
(CAMHB) starting from 256 lg/ml till 0.25 lg/ml in a micro-
titre plate as described by CLSI (2006).20
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were used for the procedure. The turbidity was adjusted with
sterile distilled water to 0.5 McFarland standard. Then 100 ll
of the (diluted 1:100) isolate was added to an equal volume
of antimicrobial solution in each well in the microtitre plate,
to reach a ﬁnal density = 5 · 105 cfu/ml.
Inoculated and uninoculated antibiotic-free broth as well as
a complete set of antibiotic dilutions for the reference P. aeru-
ginosa strain (ATCC 27853) were included. Then the microtitre
plates were incubated at 37 C overnight.
The MIC was recorded as the lowest concentration of anti-
biotic that completely inhibits the growth of the organism.
3. Results
Out of 2079 cultured specimens, 150 isolates of non fermenta-
tive gram negative bacilli (NFGNB) were found to be oxidase
positive. Only 91 of these oxidase positive isolates were able to
grow on BCSA. Out of these 91 strains growing on BCSA, 77
(84.6%) were lysine decarboxylase positive and 58 (63.7%)
were ornithine decarboxylase positive. Thirty-ﬁve (38.5%)
strains were lysine decarboxylase positive, ornithine decarbox-
ylase positive and motile fulﬁlling the basic criteria for bio-
chemical identiﬁcation of Bcc which was further conﬁrmed
by RapId NF plus.
The highest percent (85.7%) of B. cepacia complex con-
ﬁrmed isolates by RapID NF Plus were from pus specimens,
11.4% were from sputum specimens and 2.9% were from urine
specimens.
Most of strains (68.1%) were from burn unit – which were
all pus specimens- followed by dermatology unit (8.7%) then
chest unit (5.8%) and the remaining units showed the same iso-
lation percent (2.9%).Table 1 Biochemical proﬁle of 35 Bcc isolates identiﬁed by RapID
Biochemical reactionsa Proﬁle no
1 2
ADH  
TRD  
EST + +
PHS + +
NAG  
aGLU  
Bglu  
ONPG  
URE  
GLU  
PRO + +
PYR  
GGT  +
TRY  
BANA  
IND  
NO3  +
Number of strains 2 15
Percentage (%) 5.8 42.8
a ADH (Arginine dehydrogenase), TRD (Aliphatic thiol), EST (Trigl
acetyl-b,d-glucoside), aGLU (q-nitrophenyl-a,d-glucoside), bGLU (q-nitr
(Urea), GLU (glucose), PRO (Proline-b-naphthylamide), PYR (Pyrrol
(Tryptophane b-naphthylamide), BANA (N-Benzul-arginine-b-naphthylaIdentiﬁcation by RapID NF Plus:
Conﬁrmation of identity and proﬁling of the Bcc isolates
are shown in Table 1.
All strains were found to be multidrug resistant (resistant to
three or more antimicrobial classes).
Altogether, 17 different antibiotic resistance patterns were
observed as shown in Table 2. A total of 8 proﬁles were unique
but 9 proﬁles were common to 2 or more isolates.
It was found that 5 strains; No. 2, 8, 12, 25, 26 that shared
the antibiotic resistance pattern (TE, SXT, CIP, TZP), 4
strains; No. 6, 7, 20, 22 that shared the antibiotic resistance
pattern (TE, SXT, CIP, C, TZP), 3 strains; No. 1, 13, 15 that
shared the antibiotic resistance pattern (CAZ, TE, SXT, CIP,
TOB, C), 3 strains; No. 4, 14, 23 that shared the antibiotic
resistance pattern (TE, SXT, CIP, TOB, C, TZP) and 2 strains;
No. 9,11 that shared the antibiotic resistance pattern (CAZ,
TE, SXT, CIP, TZP) were isolated from specimens received
from the burn unit.
Bcc was most susceptible to ceftazidime (45.7%) and
meropenem (34.5%) followed by tobramycin (22.9%), and
they were found to have 100% resistance to trimethoprim-sul-
phamethoxazole and ciproﬂoxacin. Chloramphenicol had
intermediate susceptibility (37.1%) (see Fig. 1).
Microbroth dilution for ceftazidime showed that out of 35
strains, 16 strains were sensitive with MIC between 2–8 lg/ml,
5 strains were of intermediate sensitivity (16 lg/ml) and the
remaining 14 strains were resistant with MICP 32 lg/ml.
Out of which 10 strains had MIC 256 lg/ml indicating a higher
level of resistance to ceftazidime. As for meropenem, 12 strains
were sensitive at MIC between 0.5–4 lg/ml, 19 strains of inter-
mediate sensitivity 8 lg/ml and the remaining 4 strains wereNF Plus.
3 4 5 6
   
   
+ +  +
+ + + +
   +
   
   +
   
   
   +
+   
   
+ + + +
   
   
   
   +
11 5 1 1
31.4 14.2 2.9 2.9
yceride), PHS(q-nitrophenyl-phosphoester), NAG (q-nitrophenyl-n-
ophenyl-b,d-glucoside), ONPG (q-nitrophenyl-b,d-galactoside), URE
idine-b-naphthylamide), GGT (c-Glutamyl-b-naphthylamide, TRY
mide), IND(Tryptophane) and NO3 (Sodium nitrate).
Table 2 Antibiotic resistance pattern of the 35 Bcc strains as
detected by Bauer Kirby single disk diffusion technique.
Isolate no Total Antibiotica resistance pattern
2, 8, 12, 25, 26 5 TE, SXT, CIP, TZP
6, 7, 20, 22 4 TE, SXT, CIP, C, TZP
10, 21, 28, 34 4 CAZ, TE, SXT, CIP, TOB, C, TZP
1, 13, 15 3 CAZ, TE, SXT, CIP, TOB, C
4, 14, 23 3 TE, SXT, CIP, TOB, C, TZP
3, 18 2 TE, SXT, CIP, TOB, TZP
9, 11 2 CAZ, TE, SXT, CIP, TZP
17, 24 2 TE, SXT, CIP, TOB
19, 31 2 CAZ, TE, MEM, SXT, CIP, TOB, C, TZP
5 1 CAZ, TE, SXT, CIP, C, TZP
16 1 CAZ, TE SXT, CIP, TOB
27 1 TE, SXT, CIP, C
29 1 TE, SXT, CIP, TOB, TZP
30 1 TE, SXT, CIP
32 1 TE, MEM, SXT, CIP, TOB, C, TZP
33 1 CAZ, SXT, CIP, TOB, C, TZP
35 1 MEM, SXT, CIP, TOB
a CAZ (ceftazidime), TE (tetracycline), SXT (trimethoprim-sul-
phamethoxazole), CIP (ciproﬂoxacin), TOB (tobramycin), C
(chloramphenicol), TZP (Piperacillin–tazobactam), MEM
(meropenem).
Fig. 1 Percentage of resistant strains of B. cepacia complex to
different antimicrobial agents by the Bauer Kirby single disk
diffusion technique.
Fig. 2 MIC range of Meropenem an
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meropenem (see Fig. 2).
4. Discussion
B. cepacia complex is now added to the list of nosocomial
pathogens that cause serious problems in clinical settings
because of its high transmissibility between hospitalized
patients and its multiple drug resistance.4–6
Out of the 2079 clinical specimens received in the Microbi-
ology Laboratory, from all hospital clinical Departments
(medical wards, surgical wards and ICUs), 150/2079 (7%) iso-
lates of NFGNB were found to be oxidase positive from which
35/150 (23%) isolates were conﬁrmed as Bcc by RapID NF
Plus. The highest rate of isolation from oxidase positive
NFGNB of Bcc was from pus 30/35 (85.7%) followed by spu-
tum 4/35 (11.4%) and urine 1/35 (2.9%).
Other studies reported higher rates of isolation of B. cepa-
cia complex from specimens other than those in our study.
Gales et al. (2005)3 found that out of 176 NFGNB (83/176)
belonging to Burkholderia spp.: 52/83 (62.7%) were from
blood, 25/83 (30.1%) were from sputum, 3 (3.6%) were from
skin and soft tissue infection and 3 (3.6%) were from urine.
On the other hand, in a Turkish University Hospital, Diz-
bay et al.21 in 2009 showed, that 39 strains of Bcc were isolated
from various clinical specimens obtained from hospitalized
patients mainly in the ICU and this constituted 1.0% of gram
negative isolates and was thus considered as a rare cause of
nosocomial infection in this hospital.
In our study, out of 150 NFGNB oxidase positive isolates,
91 (61%) were able to grow on BCSA, 35/91 (38%) were pre-
liminarily identiﬁed as Bcc by motility, lysine and ornithine
decarboxylases and were conﬁrmed by RapID NF Plus. The
choice of BCSA in this study was based on the ﬁndings of
Henry et al. in 199922 and Eram et al. in 2004.17
The current study shows that most of Bcc strains isolated
were from Alexandria Main University Hospital surgical
wards 27/35 (77.1%), and the highest isolation among the sur-
gical wards was from the Burn unit 24/35 (68%). This may be
attributed to signiﬁcant thermal injuries that induce a state of
immunosuppression, in burn patients, also the devitalized tis-
sue and moist burn are favorable conditions for colonization
of micro-organisms and subsequent infection and dispersion.23d ceftazidime of B. cepacia strains.
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with motility in our study for the preliminary identiﬁcation
of B. cepacia as well as the elimination of other oxidase posi-
tive NFGNB organisms that grew on BCSA (Ralstonia spp.
and Pandoraea spp.) was based on other similar studies using
biochemical tests for preliminary identiﬁcation.10,17,24 This
was further conﬁrmed by the RapID NF Plus commercial sys-
tem, giving the above mentioned biochemical tests in combina-
tion with BCSA an important value in preliminary
identiﬁcation of B. cepacia.
A study by Shelly et al.25 in 2000 identiﬁed Bcc by different
commercial systems and concluded that although misidentiﬁ-
cation is widespread; the RapID NF Plus was accurate, truly
rapid, easy to use and the results were easy to interpret, rela-
tively reproducible when compared with those of the API
20NE and Vitek systems prior to supplemental testing.
Because the RapID NF Plus system is enzyme based and uses
carbon substrate assimilation, its ability to identify weakly oxi-
dizing B. cepacia isolates and atypical P. aeruginosa isolates
may be enhanced compared with those of the other commer-
cial systems.
In our study, we therefore relied on the RapID NF Plus sys-
tem for conﬁrming the preliminary identiﬁcation of the 35
strains of Bcc.
The most common proﬁle was proﬁle 2 which includes
42.8% of Bcc strains by a level of discrimination 95% followed
by proﬁle 3 which includes 31.4% of the strains by a level of
discrimination 99.8% (Table 1). Fifteen strains belonging to
proﬁle 2 and 3 were found in the burn unit, concluding that
the most common proﬁles were in burn unit.
In the current study, according to the results of antibiotic
susceptibility testing by the disk diffusion method, isolates of
Bcc were most susceptible to meropenem (31/35, 88.5%) fol-
lowed by ceftazidime (21/35,60%), tobramycin (14/35, 40%),
chloramphenicol (13/35, 37.1%), piperacillin/tazobactam (9/
35, 25.7%) and tetracycline (2/35, 5.8%). All strains (35/35,
100%) were resistant to both co-trimoxazole and ciproﬂoxacin.
Since their recognition in 1992, several studies tested Bcc
for antibiotic susceptibility.7,21 They all agreed that this organ-
ism was highly resistant to multiple antibiotics. Gautam et al.7
in 2009 tested 30 isolated strains of Bcc and they found that
their isolates were susceptible to piperacillin–tazobactam (26/
30, 86.7%), levoﬂoxacin (25/30, 83.3%), ceftazidime (24/30,
80%) and tetracycline (23/30, 76.7%). Amongst these 30 iso-
lates; maximum resistance was against meropenem (11/30,
36.7%) and co-trimoxazole (7/30, 23.3%).
Disbay et al.21 in 2009 tested 39 nosocomial strains. They
reported that their B. cepacia isolates were most resistant to
ceftazidime (24/39, 61.5%), followed by amikacin and cipro-
ﬂoxacin (21/39, 53.8%) each, then meropenem (19/39,
48.7%), co-trimoxazole (22/39, 56.4%) and piperacillin–tazo-
bactam (15/39, 38.4%).
Comparing the results of our study to those two studies we
observe that our strains were more sensitive to meropenem
(88.5%) than (51.3%) in Disbay et al. and (36.7%) in Gautam
et al. but our strains were less sensitive to ceftazidime (60%)
than those of Gautam et al. (80%), yet the least sensitivity
to ceftazidime was reported by Disbay et al. (38.5%).
More discrepancies are observed as regards piperacillin–
tazobactam, where B. cepacia complex strains in the study of
Gautam et al. and Disbay et al. were more sensitive to thisantibiotic than those tested in our study showing 86.7%,
61.6%, 25.7% sensitivity respectively. On the other hand none
of the 35 B. cepacia complex strains in our study were sensitive
to ciproﬂoxacin, yet 83.3% of Gautam et al. strains and 46.2%
of Disbay et al. strains were sensitive to it.
The three studies agree that resistance to co-trimoxazole is
common, only 23.8% of Gautam et al. strains and 43.6% of
Disbay et al. strains were sensitive to it. However, our strains
were 100% resistant to co-trimoxazole, although this drug was
considered to be effective in treating cases of CF in earlier
studies, and some cases of nosocomial infection. Those varia-
tions of antibiotic susceptibility results between different coun-
tries are probably explained by the different antibiotic policies
used.26,27 These ﬁndings, also emphasize even more the need to
isolate and test reliably more strains of Bcc to review the ther-
apeutic measures. Determining the MIC of signiﬁcant antibiot-
ics that are still active on Bcc as tested by the modiﬁed Bauer
Kirby test is therefore imperative.
In the current study, ceftazidime and meropenem were the
antibiotics selected for testing their MIC on the 35 Bcc strains
by the microbroth dilution method. The results of these tests
conformed perfectly with the results of the modiﬁed Bauer Kir-
by disk diffusion technique for both antibiotics.
Gales et al. (2005)3 in a large antimicrobial surveillance
program between 1997 and 2002 studied the MIC of ceftazi-
dime and meropenem as well as others isolated from Latin
America. They found that susceptibility rates slightly varied
from 79.5% for meropenem to 83.1% for ceftazidime. In their
study ceftazidime (MIC50, 4 lg/ml; 83.1% susceptibility) was
the most active b-lactam against Bcc in contrast to results
reported by other studies that showed Meropenem as the most
active b-lactam.28,29 Our study agrees with Visalli et al. and
Bonacorsi et al. where if the total susceptibility of our B. cepa-
cia complex strains is taken into account; 88.5% of our B.
cepacia complex strains were inhibited by meropenem while
only 60% of these strains were inhibited by ceftazidime.
Apparently, even MIC results conﬁrm that for the time being,
meropenem is the best therapeutic option for Bcc infections in
our Alexandria Main University Hospital.29,30
In the current study, the antibiotic resistance pattern of the
35 Bcc revealed that altogether the 35 strains were distributed
among 17 different resistance proﬁles. The largest cluster of
strains of identical resistance proﬁle was from patients in the
burn unit where 5 strains shared the resistance pattern TE,
SXT, CIP, TZP and 4 strains shared the resistance pattern
TE, SXT, CIP, TZP, C with resistance to Chloramphenicol
as the only added minor variation so the 9 strains could be
safely accepted to have almost identical resistance pattern
which may implicate a common source or origin. In addition,
3 strains shared the antibiotic resistance pattern CAZ, TE,
SXT, CIP, TOB, C and another 3 shared the pattern TE,
SXT, CIP, TOB, C, TZP. This ﬁnding requires further study
of the environment in the burn unit in the near future. More
strains of Bcc are to be isolated and typed from both the
patients and the hospital environment to detect the source of
cross contamination and infection.Conﬂict of interest
The authors declare no conﬂict of interest.
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